ImmunityBio, Inc.(IBRX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,451 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
IBRX Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for ImmunityBio, Inc. (IBRX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IBRX at 31.5/100 on a 32-signal composite quality model, placing it at rank #2,451 of 2,961 stocks — the bottom half of the AI-ranked universe. IBRX scores in the top quartile across revenue growth (99.3). Areas of concern include balance sheet strength (0.4) and profitability (3.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ImmunityBio, Inc. reports quarterly revenue of $51.2M, net income of $-230.4M, free cash flow of $-70.0M. Top institutional holders of IBRX by reported 13-F value include BlackRock, STATE STREET, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. IBRX trades on the Nasdaq exchange and files with the SEC under CIK 1326110. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IBRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ImmunityBio, Inc. directly from SEC EDGAR. ImmunityBio, Inc.'s 13F Pro composite quality score has ranged between 10 and 34 since 2021, currently 31.5 — an improving long-term trajectory across 67 quarterly and live scoring snapshots.
Revenue
Q2 2026
$51.2M
Net Income
Q2 2026
$-230.4M
Free Cash Flow
Q2 2026
$-70.0M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+668.3% YoYNet Income
+15.0% YoYOperating Income
+25.6% YoYEPS (Diluted)
+38.7% YoYTotal Assets
+31.1% YoYTotal Debt
+40.3% YoYOp. Cash Flow
+22.1% YoYFree Cash Flow
+22.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $113.3M +668.3% | $14.7M +2270.6% | $622.0K +159.2% | $240.0K -74.3% | $934.0K +54.4% | $605.0K |
| Net Income | $-351.4M +15.0% | $-413.6M +29.1% | $-583.2M -40.0% | $-416.6M -20.1% | $-346.8M -56.3% | $-221.9M |
| Operating Income | $-256.0M +25.6% | $-344.2M +5.0% | $-362.3M -3.1% | $-351.3M -6.4% | $-330.3M -49.5% | $-220.9M |
| EPS (Diluted) | $-0.38 +38.7% | $-0.62 +46.1% | $-1.15 -10.6% | $-1.04 -16.9% | $-0.89 -50.8% | $-0.59 |
| Total Assets | $501.9M +31.1% | $382.9M -24.1% | $504.5M +39.2% | $362.4M -22.7% | $468.9M +111.8% | $221.4M |
| Total Debt | $1.8M +40.3% | $1.2M | — | — | — | — |
| Operating Cash Flow | $-304.9M +22.1% | $-391.2M -6.7% | $-366.8M -8.7% | $-337.5M -23.0% | $-274.4M -59.8% | $-171.7M |
| Free Cash Flow | $-308.8M +22.4% | $-398.1M -0.2% | $-397.3M +4.4% | $-415.7M -35.0% | $-308.0M -77.6% | $-173.4M |
Get alerted when IBRX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for ImmunityBio, Inc. including:
Top Institutional Holders of IBRX
BlackRock, Inc.
$298.4M34,083,262 shSTATE STREET CORP
$187.3M21,398,438 shVANGUARD PORTFOLIO MANAGEMENT LLC
$156.4M17,863,911 shVANGUARD CAPITAL MANAGEMENT LLC
$137.4M15,691,579 shD. E. Shaw & Co., Inc.
$101.1M11,551,019 shTWO SIGMA INVESTMENTS, LP
$97.2M11,097,106 shGEODE CAPITAL MANAGEMENT, LLC
$86.2M9,847,896 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$58.1M6,627,600 shGROUP ONE TRADING, L.P.
$49.4M5,643,800 shMILLENNIUM MANAGEMENT LLC
$48.9M5,579,793 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $298.4M | 34,083,262 |
| STATE STREET CORP | $187.3M | 21,398,438 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $156.4M | 17,863,911 |
| VANGUARD CAPITAL MANAGEMENT LLC | $137.4M | 15,691,579 |
| D. E. Shaw & Co., Inc. | $101.1M | 11,551,019 |
| TWO SIGMA INVESTMENTS, LP | $97.2M | 11,097,106 |
| GEODE CAPITAL MANAGEMENT, LLC | $86.2M | 9,847,896 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $58.1M | 6,627,600 |
| GROUP ONE TRADING, L.P. | $49.4M | 5,643,800 |
| MILLENNIUM MANAGEMENT LLC | $48.9M | 5,579,793 |
Companies Similar to IBRX
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
IOVANCE BIOTHERAPEUTICS, INC.
PRECIGEN, INC.
RHYTHM PHARMACEUTICALS, INC.
AbCellera Biologics Inc.
Invivyd, Inc.
Janux Therapeutics, Inc.
CYTOKINETICS INC
Kura Oncology, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put IBRX on your watchlist
Track score changes the day ImmunityBio, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is IBRX a good stock to buy?
13F Pro's AI-powered analysis of ImmunityBio, Inc. (IBRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IBRX are available on the IBRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. IBRX is classified as a mid company.
Which hedge funds own IBRX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IBRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ImmunityBio, Inc.'s investment landscape.